Should an elevated lipoprotein(a) be treated in a 57-year-old man with normal renal function, normal blood pressure, HDL cholesterol of 69 mg/dL, total cholesterol of 196 mg/dL, and LDL cholesterol of 101 mg/dL?

Should You Treat Elevated Lp(a) in This Patient?

Yes, you should aggressively manage this patient's cardiovascular risk factors, particularly by intensifying LDL-lowering therapy, even though his LDL is 101 mg/dL. While Lp(a) itself is not currently a direct treatment target, an elevated Lp(a) ≥50 mg/dL (≥100 nmol/L) in primary prevention mandates earlier and more intensive management of all modifiable ASCVD risk factors 1.

Risk Stratification with Elevated Lp(a)

This 57-year-old man with elevated Lp(a) faces significantly increased cardiovascular risk despite his seemingly favorable lipid profile. Elevated Lp(a) acts as a risk-enhancing factor that should lower your threshold for aggressive intervention 1.

The 2021 Canadian Cardiovascular Society guidelines explicitly state that finding high Lp(a) should alert practitioners to:

• More actively pursue overall ASCVD risk assessment
• Consider earlier introduction of statin therapy, especially in intermediate-risk individuals
• Consider earlier therapy even in low-risk individuals with LDL-C between 3.5-5 mmol/L (135-193 mg/dL) 1

At 101 mg/dL, his LDL is in the range where elevated Lp(a) justifies initiating lipid-lowering therapy.

Specific Treatment Approach

1. Initiate Statin Therapy

Start a moderate-to-high intensity statin immediately. The goal is to achieve at least a 30-40% reduction in LDL-C 2. For this patient, target an LDL-C <70 mg/dL given the risk enhancement from elevated Lp(a) 2.

Rationale: While statins don't lower Lp(a) (and may modestly increase it), aggressive LDL-C lowering is the cornerstone of managing residual risk from elevated Lp(a) 1, 3.

2. Consider PCSK9 Inhibitors

If LDL-C remains >70 mg/dL on maximally tolerated statin therapy, add a PCSK9 inhibitor (evolocumab or alirocumab). These agents:

• Lower LDL-C by 50-60%
• Reduce Lp(a) by 20-30% as a secondary effect
• Have shown benefit in reducing MACE independent of LDL-C lowering in patients with elevated Lp(a) 1, 3

The FOURIER and ODYSSEY OUTCOMES trials demonstrated that PCSK9 inhibitors reduce cardiovascular events in patients with elevated Lp(a), with some evidence suggesting benefit independent of LDL-C reduction 1.

3. Intensify Lifestyle Modifications

Earlier and more intensive health behavior modification counseling is specifically recommended for primary prevention patients with Lp(a) ≥50 mg/dL 1:

• Smoking cessation (if applicable)
• Mediterranean-style diet emphasizing unsaturated fats, limiting saturated fat to <7% of calories
• Regular aerobic exercise (at least 30 minutes most days)
• Weight optimization if BMI >25 kg/m²
• Limit alcohol to ≤1-2 drinks daily

4. Optimize All Other Risk Factors

Since you cannot directly lower Lp(a) with current therapies, every other modifiable risk factor becomes more critical:

• Maintain blood pressure <130/80 mmHg (already normal in this patient)
• Screen for diabetes/prediabetes with HbA1c
• Consider aspirin 75-160 mg daily for primary prevention if 10-year ASCVD risk ≥10% 4

5. Consider Advanced Risk Assessment

For shared decision-making, consider:

• Coronary artery calcium (CAC) scoring to detect subclinical atherosclerosis 1
• If CAC >0, this further justifies aggressive therapy
• Calculate 10-year ASCVD risk using Framingham or pooled cohort equations

What NOT to Do

Common pitfalls to avoid:

• Don't use niacin - it lowers Lp(a) but has not been shown to reduce cardiovascular or all-cause mortality and is now contraindicated for this purpose 3
• Don't wait - the "LDL is only 101" mindset ignores the independent risk from Lp(a)
• Don't repeat Lp(a) measurements - levels are genetically determined and stable throughout life 1
• Don't assume statins alone are sufficient - elevated Lp(a) represents residual risk even with optimal LDL-C lowering

Family Screening

Screen first-degree relatives for elevated Lp(a), as it is >90% heritable 1. This is particularly important given the strong genetic component and the fact that approximately 20% of the general population has elevated levels.

Future Considerations

While not currently available, RNA-based therapies (antisense oligonucleotides like pelacarsen and siRNAs like olpasiran) are in late-stage trials and achieve 80-95% Lp(a) reductions 3, 5. Document this patient's elevated Lp(a) clearly in the medical record so he can be considered for these therapies once approved.

Lipoprotein apheresis (which reduces Lp(a) by 60-75%) is FDA-approved but reserved for patients with progressive ASCVD despite maximal medical therapy and Lp(a) >60 mg/dL or >125 nmol/L 3.

The Bottom Line

Lp(a) is not currently a treatment target, but it absolutely changes how aggressively you manage everything else. This patient needs statin therapy now, with a target LDL-C <70 mg/dL, intensive lifestyle modification, and consideration for PCSK9 inhibitor therapy if targets aren't met. The elevated Lp(a) transforms him from a "borderline" candidate for therapy into someone who clearly benefits from aggressive risk factor modification.